

PHARMEDIC
PHAMACEUTICAL MEDICINAL JOIN STOCK
367 Nguyen Trai street, Cau Ong Lanh Ward, HCM city
Tax code: 0300483037

FINANCIAL REPORT

2TH QUARTER 2026

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

STATEMENT OF FINANCIAL POSITION

As at 30th June 2026

Currency: VND

	Code	Notes	Ending balance of period	Beginning balance
1	2	3	4	5
ASSETS				
A. CURRENT ASSETS AND SHORT-TERM INVESTMENTS	100		272.417.191.393	219.575.579.955
I. Cash and cash equivalents	110		32.563.728.545	40.564.104.864
1. Cash	111		12.563.728.545	40.564.104.864
2. Cash equivalents	112		20.000.000.000	-
II. Short-term financial investments	120		500.000.000	500.000.000
3. Held-to-maturity investments	123		500.000.000	500.000.000
III. Accounts receivable	130		82.499.740.472	66.222.733.916
1. Short-term trade receivables	131		51.823.851.593	34.720.871.572
2. Short-term advance payments to suppliers	132		29.585.979.397	31.775.158.531
3. Phải thu nội bộ ngắn hạn	133			
4. Phải thu theo tiến độ kế hoạch hợp đồng xây dựng	134			
5. Other short-term receivables	135		2.195.566.536	781.298.114
6. Provisions for doubtful debts (*)	136		(1.105.657.054)	(1.054.594.301)
7. Deficit assets for treatment	137			
IV. Inventories	140		146.967.785.836	103.930.108.712
1. Inventories	141		146.967.785.836	103.930.108.712
2. Provision for obsolete inventory (*)	142			
V. Short-term biological assets	150		-	-
VI. Other current assets	160		9.885.936.540	8.358.632.463
1. Short-term livestock for one-time product harvest	161		7.148.603.659	3.563.540.430
2. VAT deductible	162		2.737.332.881	4.795.092.033
3. Tax receivables	163			-
4. Other current assets	165		-	-
B - FIXED ASSETS AND LONG-TERM INVESTMENTS	200		140.592.328.960	125.848.483.770
I. Long-term receivables	210		-	-
II. Fixed assets	220		115.773.412.138	93.214.840.011
1. Tangible fixed assets	221		100.653.892.102	91.217.110.307
- Historical cost	222		307.980.716.064	289.180.699.098
- Accumulated depreciation (*)	223		(207.326.823.962)	(197.963.588.791)
2. Finance lease fixed assets	224		-	-
- Historical cost	225			
- Accumulated depreciation (*)	226			
3. Intangible fixed assets	227		15.119.520.036	1.997.729.704
- Historical cost	228		21.587.764.909	8.057.764.909
- Accumulated amortization (*)	229		(6.468.244.873)	(6.060.035.205)
III. Long-term biological assets	230		-	-
IV. Investment Properties	240		-	-
- Historical cost	241			
- Accumulated depreciation (*)	242			

	Code	Notes	Ending balance of period	Beginning balance
1	2	3	4	5
V. Non-current unfinished assets	250		176.707.519	2.418.130.548
1. Long-term work-in-process	251			
2. Construction-in-progress	252		176.707.519	2.418.130.548
V. Long-term financial investments	260		-	-
VI. Other non-current assets	270		24.642.209.303	30.215.513.211
1. Long-term deferred expenses	271		24.642.209.303	30.215.513.211
TOTAL ASSETS (280 = 100 + 200)	280		413.009.520.353	345.424.063.725
RESOURCES				
C - LIABILITIES	300		160.519.256.960	104.568.735.717
I. Current liabilities	310		160.519.256.960	104.568.735.717
1. Short-term trade payables	311		27.574.862.540	28.534.924.569
2. Short-term advance payments from customers	312		1.681.830.588	1.940.919.537
3. Dividends and profits payable	313		13.642.951.454	15.240.981.474
4. Tax and statutory obligations	314		6.696.252.652	8.065.664.348
5. Payables to employees	315		17.358.240.775	38.343.369.723
6. Short-term accruals	316		234.395.156	
7. Short-term inter-company payables	317			
8. Construction contractor payables based on agreed progress billings	318			
9. Short-term unearned revenue	319			
10. Other short-term payables	320		1.453.611.372	561.441.445
11. Short-term finance lease loans and liabilities	321		86.866.706.751	181.005.840
12. Provisions for short-term payables	322			4.318.000.000
13. Bonus and welfare funds	323		5.010.405.672	7.382.428.781
14. Price stabilization fund	324			
15. Government bond repurchase transaction	325			
II. Non-current liabilities	330		-	-
D - OWNERS' EQUITY	400		252.490.263.393	240.855.328.008
1. Owners' invested equity	411		93.325.730.000	93.325.730.000
- Common stocks with voting rights	411a		93.325.730.000	93.325.730.000
- Preferred stocks	411b			
2. Surplus of share capital	412		972.972.000	972.972.000
3. Bond conversion option	413			
4. Other capital of the owner	414			
5. Treasury stock (*)	415			
6. Asset revaluation differences	416			
7. Exchange rate differences	417			
8. Development and investment funds	418			93.250.277.906
9. Other funds of the owner's capital	419			
10. Undistributed earnings after tax	420		158.191.561.393	53.306.348.102
- Accumulated undistributed earnings after tax to the end of previous year	420a		130.675.743.378	340.988.541
- Accumulated undistributed earnings after tax in current year	420b		27.515.818.015	52.965.359.561
TOTAL RESOURCES (440 = 300 + 400)	440		413.009.520.353	345.424.063.725

Prepared by


Trần Mạnh Hùng

Chief Accountant

Văn Diệu Lê

Approve, 14th July 2026

General Director



PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

INCOME STATEMENT

As at 30th June 2026


Currency: VND

ITEMS	Code	Notes	1rd Quarter of current year	1rd Quarter of previous year	Accumulated from the beginning of year to the end of this quarter	
					Current year	Previous year
1. Revenues from sale of goods and rendering of services	01		120.378.002.770	132.266.368.659	261.929.869.436	257.955.509.217
2. Revenue deductions	02		1.315.248.669	11.673.430	4.258.947.953	32.351.722
3. Net revenues from sale of goods and rendering of services	10		119.062.754.101	132.254.695.229	257.670.921.483	257.923.157.495
4. Cost of goods sold	11		69.175.620.468	75.663.566.183	146.694.573.957	146.658.195.453
5. Gross profit from sale of goods and rendering of services	20		49.887.133.633	56.591.129.046	110.976.347.526	111.264.962.042
6. Profit/loss from the liquidation of investment properties	21					
7. Income from financial activities	22		182.653.083	1.698.955.981	192.324.851	2.903.041.929
8. Expenses from financial activities	23		1.537.766.614	42.739.726	1.974.197.460	42.739.726
In which: Interest expenses	24		1.537.766.614	42.739.726	1.974.197.459	42.739.726,00
9. Selling expenses	25		17.287.590.653	14.682.391.369	33.841.332.959	29.477.255.192
10. General & administration expenses	26		14.428.225.532	15.507.093.454	29.851.125.991	28.880.478.054
11. Net profit/(loss) from operating activities	30		16.816.203.917	28.057.860.478	45.502.015.967	55.767.530.999
12. Other income	31		27.781.111	45.001.858	74.267.107	709.547.313
13. Other expenses	32		34.781	92.820.802	76.435.556	92.820.802
14. Other profit	40		27.746.330	(47.818.944)	(2.168.449)	616.726.511
15. Total pre-tax accounting profit	50		16.843.950.247	28.010.041.534	45.499.847.518	56.384.257.510
16. Current Corporate Income tax expenses	51		3.419.850.049	5.647.188.307	9.151.029.503	11.322.031.502
17. Deferred Corporate Income tax expenses	52		-	-	-	-
18. Profit/(loss) after corporate income tax	60		13.424.100.198	22.362.853.227	36.348.818.015	45.062.226.008
19. Gains on stock (*)	70		1.089	1.814	2.948	3.655
20. Declining returns on stocks (*)	71		1.089	1.814	2.948	3.655

Prepared by

Chief Accountant


Trần Mạnh Hùng


NGUYỄN DIỆU LÊ

Báo cáo này phải được đọc kèm với Thuyết minh báo cáo tài chính

Approve, 14th July 2026

General Director



PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

C+

STATEMENT OF CASH FLOW

As at 30th June 2026

(As per Indirect Method)

Currency: VND

ITEMS	Code	Notes	Accumulated from the beginning of year to the end of this quarter	
			Current year	Previous year
I. Cash flows from operating activities				
1. Net profit/(loss) before tax	01		45.499.847.518	56.384.257.510
2. Adjustments for :			11.796.705.052	2.318.900.968
Depreciation and amortisation	02		9.771.444.839	5.428.495.088
Provisions	03		51.062.753	39.280.106
Exchange rate gains and losses resulting from the revaluation of monetary items denominated in foreign currencies.	04		-	-
Profit and loss from investment and financial activities	05		-	(3.191.613.952)
Interest expense	06		1.974.197.460	42.739.726
3. Operating income/(loss) before changes in working capital	08		57.296.552.570	58.703.158.478
(Increase) / decrease in receivables	9		(14.270.310.157)	(29.926.420.677)
(Increase)/decrease in inventory	10		(43.037.677.124)	(46.323.227.919)
Increase/(decrease) in payables (excluding interest payable, PIT payables)	11		(27.351.606.130)	19.565.521.735
Increase or decrease in deferred expenses	12		1.880.222.160	(11.776.667.095)
Increase or decrease in trading securities	13		-	-
Interest paid	14		(1.974.197.460)	-
Corporate income tax paid	15		(12.559.671.718)	(11.679.568.447)
Other cash inflows from operating activities	16		-	-
Other cash outflows from operating activities	17		(14.020.303.539)	(15.572.237.217)
Net cash inflows/(outflows) from operating activities	20		(54.036.991.398)	(37.009.441.142)
II. Cash flows from investing activities				
1. Purchase of fixed assets and other long-term assets	21		(26.141.196.541)	(27.346.364.604)
2. Proceeds from disposals of fixed assets and other long-term assets	22		-	664.545.455
3. of other entities	23		-	(111.500.000.000)
4. other entities	24		-	160.500.000.000
5. Payments for investments in other entities	25		-	-
6. Proceeds from sales of investments in other entities	26		-	-
7. Interest and dividends received	27		-	3.606.752.055
Net cash inflows(outflows) from investing activities	30		(26.141.196.541)	25.924.932.906
III. Cash flows from financing activities				
1. Proceeds from issue of stocks, capital contribution of the owner	31		-	-
2. Capital redemption of the owners, the acquisition of issued stocks	32		-	-
3. Money received from borrowing	33		86.866.706.751	20.000.000.000
4. Repayments of borrowing principal	34		(181.005.840)	-
5. Repayments of finance lease principal	35		-	-
6. Dividends, gains paid to the owner	36		(14.507.889.291)	(64.015.875.300)
Net cash inflows/(outflows) from financing activities	40		72.177.811.620	(44.015.875.300)
Net cash inflows/(outflows)	50		(8.000.376.319)	(55.100.383.536)
Cash and cash equivalents at the beginning of the year	60		40.564.104.864	60.084.311.574
Impact of exchange rate fluctuation	61		-	-
Cash and cash equivalents at the end of the year (70=50+60+61)	70		32.563.728.545	4.983.928.038

Prepared by

Chief Accountant

Approved, 14th July 2026

General Director

DUỘC PHÁP

DUỘC LIỆU

PHARMEDIC

THÀNH PHỐ

DUỘC LIỆU

Báo cáo này phải được đọc kèm với Thuyết minh báo cáo tài chính

NGUYỄN ĐIỀU LÊ

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.


FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Appendix : The movement on the Owners' equity

	Owners' invested equity	Surplus of share capital	Other capital of the owner	Development and investment funds	Undistributed earnings after tax (**)	Total
Beginning balance in previous year	93.325.730.000	972.972.000	-	93.250.277.906	102.062.842.363	289.611.822.269
Profit increase in previous year					82.304.932.561	82.304.932.561
Decrease in previous year					(131.061.426.822)	(131.061.426.822)
+ Make appropriation of funds					(22.168.965.058)	(22.168.965.058)
+ Dividend distribution				-	(108.892.461.764)	(108.892.461.764)
+ Other decrease					-	-
Ending balance in previous year, Beginning balance in current year	93.325.730.000	972.972.000	-	93.250.277.906	53.306.348.102	240.855.328.008
Profit increase in current year				(93.250.277.906)	36.348.818.015	(56.901.459.891)
+ Increase from business results					36.348.818.015	36.348.818.015
+ Increase from profit distribution				-	-	-
Bonus shares				-	-	-
Decrease in current year			-	-	68.536.395.276	68.536.395.276
+ Make appropriation of funds					(11.648.280.430)	(11.648.280.430)
+ Dividend distribution					(13.065.602.200)	(13.065.602.200)
+ Other decrease			-		-	-
Ending balance in current period	93.325.730.000	972.972.000	-	-	158.191.561.393	252.490.263.393

Prepared by


Manh Hung

Chief Accountant


NGUYỄN DIỆU LÊ

Approve, 14th July 2026

General Director



DS. LÊ VIỆT HÙNG

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

NOTES TO THE FINANCIAL STATEMENTS**For the three-month period ended 30th June 2026**

These notes form an integral part of and should be read in conjunction with the Financial Statements for the three-month period ended 30th June 2026 of Pharmedic Pharmaceutical Medicinal Joint Stock Company (hereafter, referred to as "the Company").

I. OPERATION FEATURES**1. Forms of ownership**

Joint stock company.

Pharmedic Pharmaceutical Medicinal Joint Stock Company (abbreviation is: PHARMEDIC JSC) was transferred from Pharmaceutical Medicinal Public Private Joint Venture Enterprise to joint stock company in accordance with the Decision No. 4261/QĐ-UB date 13th August 1997 of the People's Committee of Ho Chi Minh city. The Business Registration Certificate No. 064075 dated 09th December 1997 granted by the Department of Planning and Investment of Ho Chi Minh city and subsequent license changes with the latest change on 04th June 2024 to change the Company representative.

Charter capital according to the Business Registration Certificate is VND 93,325,730,000 as follows:

Shareholders	As at 30th June 2026		As at 01st January 2026	
	Amount (VND)	Proportion (%)	Amount (VND)	Proportion (%)
Saigon Pharmaceutical Company Limited -	40.543.090.000	43,44	40.543.090.000	43,44
Representative of State capital				
Other shareholders	<u>52.782.640.000</u>	<u>56,56</u>	<u>52.782.640.000</u>	<u>56,56</u>
Total	93.325.730.000	100	93.325.730.000	100

2. Lines of business

Production and trading of pharmaceuticals

3. Ngành nghề kinh doanh

Production and trading of pharmaceuticals, medicinal materials, cosmetics, medical supplies and other products in the medical industry;

Joint ventures and associations with domestic and foreign organizations and individuals to process a number of raw materials (mainly from medicinal herbs to produce some traditional products);

Printing and pressing plastic, aluminum and paper packaging;

Production and trading of chemicals (except highly toxic chemicals), insecticidal and antibacterial products used in the household and medical fields (not produced at the headquarters).

Other business support service activities n.e.c, details: Joint ventures and associations with domestic and foreign individuals.

Retail sale of medicines, medical equipment, cosmetics and hygiene supplies in specialized stores, details: Retail sale of medicines, medical equipment, medical supplies and cosmetics.

Manufacture of other food products n.e.c, details: Production of functional foods

Technical testing and analysis, details: Storage services and medicine testing services.

4. Normal business and production cycle

The Company's normal business and production cycle is within 12 months.

5. The Company's operations in year affect the Aggregated financial statements

Revenue in current year increased by 0,1% compared to previous year due to higher selling prices. However, during the year, the Company has settled term deposit contracts, so income from financial activities in current year decreased significantly compared to previous year. In addition, the Company expanded its business scale (opened a branch in Hanoi), so costs from initial operating activities increased compared to previous year. From the above factors have led to pre-tax accounting profit increased by 19,3% compared to previous year.

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

7. Employees

As at 30th June 2026, there are 494 employees who are working at the Company (there were 535 employees at the beginning of year).

II. ACCOUNTING PERIOD, AND REPORTING CURRENCY

1. The Company's fiscal year

The fiscal year starts on 01st January and ends on 31st December of each calendar year.

2. Reporting currency and methods of foreign currency translation

The standard currency unit used is Vietnam Dong (VND) because the Company uses the main accounting currency unit which is Vietnam Dong (VND) for receipts and payments.

III. ADOPTED ACCOUNTING REGIME AND STANDARDS

1. Applicable accounting regime

The Company has applied the Accounting Standards and the Vietnamese Corporate Accounting System in accordance with the Circular No. 99/2025/TT-BTC dated 27nd October 2025 as well as circulars guidance on implementing the accounting standards of the Ministry of Finance in the preparation and presentation of the Financial statements.

Whereby, the accompanying financial statements, Income Statement, Statement of Cash Flows and Notes to the Financial Statements for the fiscal year and the use of this report is not intended for subjects who are not provided information on the procedures and principles and accounting practices in Vietnam, as well as not intentionally presented the financial position, the business results and the cash flows under the procedures and principles and accounting practices widely accepted in other countries and territories outside Vietnam.

2. Statement on the compliance with the Vietnamese accounting regime and standards

We, the Board of Directors of Pharmedic Pharmaceutical Medicinal Joint Stock Company ensure to follow all the requirements of the accounting standards and the Vietnamese Corporate accounting system promulgating together with the Circular No. 99/2025/TT-BTC dated 27nd October 2025 as well as circulars guidance on implementing the accounting standards of the Ministry of Finance in the preparation of the Financial statements.

IV. ADOPTED ACCOUNTING POLICIES

1 Basic for preparing the aggregated Financial statements

The aggregated Financial statements are prepared based on accrual accounting (excluding information related to the cash flows).

2. Cash and cash equivalents

Cash includes cash on hand, call deposits and cash in transit, monetary gold.

Cash equivalents is the short-term securities of which the due dates can not exceed 3 (three) months from the dates of the investments and the convertibility into cash is easy, and which do not have a lot of risks in the conversion into cash.

3. Financial investments

Held-to-maturity investments

The investments are classified as held-to-maturity if the Company has both the ability and the intention to hold to maturity. Held-to-maturity investments include: term deposits (including treasury bills, promissory note) bonds, preferred stocks which the issuance party is obligated to repurchase at a specific time in the future and held-to-maturity loans for the purpose of collecting interest periodically and other held-to-maturity investments.

Principles for determining held-to-maturity investments are initially recognized at the historical costs include purchase price and expenses related to investments transactions. After initial recognition, these investments are recognized at recoverable amount. Interest income on held-to-maturity investments after the date of acquisition are recognized in Income Statement on the basis of accrual. Interest enjoyed before the Company held is deducted against the historical cost as at the date of acquisition.

When there is certainly evidence shows part of or the entire investment may not be recoverable and the loss can be determined reliably, the loss is recognized in Expenses from financial activities in year and direct reduction of investment value.

4. Receivables

Doubtful receivables are presented by book value subtracting the provisions for doubtful receivables.

Receivables are classified as trade receivables and other receivables comply with the following principles:

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

- Trade receivables reflect the commercial elements arising from selling - purchasing transactions between the Company and the buyer is an independent entity, include receivables from export sales under entrusted others.
- Other receivables reflect the non-commercial elements, unrelated to selling - purchasing transactions.

Provision for doubtful receivables: are prepared for each doubtful debt based on the overdue debts or the estimated losses which may arise.

Increase/Decrease in the balance of provisions for doubtful receivables must be made as at the accounting period ended and are recognized in the general & administration expenses.

5. Inventories

Inventories are recognized at the lower of their historical costs or their net realizable values.

Historical costs of inventories are determined as follows:

- Raw materials, goods: including the acquisition cost and other direct related expenses arising to obtain inventory in current status and place.
- Finished goods: including the cost of direct materials, direct labor and related factory overhead cost are allocated based on normal capacity.
- Work-in-process: including only the costs of main raw materials, direct labor and general production costs.

Net realizable values is the estimated selling price of inventory in normal operating cycle except for the estimated costs to complete and necessary to consume them.

The value of inventories are recognized at the weighted average method and recorded at the perpetual method.

Provision for devaluation of inventory is made for each item based on their costs is higher than their net realizable values.

Increase/Decrease in the balance of provision for devaluation of inventory must be made as at 31st December 2025 and are recognized in the cost of goods sold.

6. Prepaid expenses

Prepaid expenses include the actual arising costs but related to the operating results of numerous accounting periods. The Company's prepaid expenses include:

Tools

Expenses on tools being put into use are allocated into expenses in accordance with the straight line method for the maximum period of 3 years.

Repair costs of fixed assets

Repair costs of assets arising once have great value are allocated into expenses in accordance with the straight line method within 3 years.

7. Tangible fixed assets

Tangible fixed assets are determined by the historical costs less (-) accumulated depreciation. Historical costs of tangible fixed assets include all the expenses of the company to have these fixed assets as of the dates they are ready to be put into use. Other expenses incurred subsequent to the initial recognition are included in historical costs of fixed assets only if they certainly bring more economic benefits in the future thanks to the use of these assets. Those which do not meet the above conditions will be recorded into expenses during the period.

When tangible fixed assets are disposed or liquidated, their historical costs and accumulated depreciation are written off, then any profit (or loss) generated from the liquidation is included in the income or the expenses during the period.

Tangible fixed assets are depreciated in line with straight-line method to gradually write off the historical costs of fixed assets over their estimated useful lives. The depreciation years of tangible fixed assets applied are as follows:

Kinds of fixed assets	Years
+ Buildings and structures	05 – 30
+ Machineries and equipments	06 – 10
+ Vehicles, transmissions	06 – 10
+ Management equipments, tools	03 – 08

8. Intangible fixed assets

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Intangible fixed assets are determined by the historical costs less (-) accumulated amortization.

Historical costs of intangible fixed assets include all the expenses of the company to have these fixed assets as of the dates they are ready to be put into use. Other expenses incurred subsequent to the initial recognition are included in expenses during the period only if they attached to the specific intangible fixed asset and bring more economic benefits thanks to the use of these assets.

When intangible fixed assets are disposed or liquidated, their historical costs and accumulated amortization are written off, then any profit (or loss) generated from the liquidation is included in the income or the expenses during the period.

The Company's intangible fixed assets include:

Land-use right

Costs related to computer software programs is not an integral part of the related hardware is capitalized. Historical costs of computer software include all the expenses of the Company to pay until the date the software is put into use. Computer software is amortized in line with straight-line method from 03 to 05 years.

Other intangible fixed assets

Costs related to computer software programs is not an integral part of the related hardware is capitalized. Historical costs of computer software include all the expenses of the Company to pay until the date the software is put into use. Computer software is amortized in line with straight-line method from 03 to 05 years.

Other intangible fixed assets

Other intangible fixed assets is amortized in line with straight-line method to gradually write off the historical costs of fixed assets over their estimated useful lives.

9. Liabilities and accruals

Liabilities and accruals are recognized for payable amounts in the future related to the received goods and services. Accruals are recognized based on the reasonable estimates of the payable amounts.

Payables are classified as trade payables, accruals, payables to employees and other payables comply with the following principles:

- Trade payables reflect the commercial elements arising from purchasing transactions of goods, services, assets and the seller is an independent entity.
- Accruals reflect the payables to the received goods and services from seller or provided to buyer but not yet paid due to do not have invoice or insufficient accounting records and vouchers and payable to employees on sabbatical salary, operating costs must be accrued.
- Payables to employees reflect payables and the payment status to employees for wages, bonus and others belonging to employees' income. The Company makes appropriation of the salary fund according to the Resolution of the Board of Management No. 38/PMC-HĐQT dated 01st August 2014 on salary coefficient rate of 56% on Total revenue minus (-) total expenses without salary.
- Other payables reflect the non-commercial elements, unrelated to selling - purchasing transactions, rendering of services.

10. Owners' equity

Owner's invested equity

Owner's invested equity is recognized according to the shareholders' actual capital.

Surplus of share capital

Surplus of share capital is recognized at differences between issued actual value and the nominal value of stocks when they first issued, supplement issue, differences between re-issued value and the book value of treasury stocks and capital structure of the convertible bonds at maturity. Direct costs related to the issuance of additional stocks and the re-issuance of treasury stocks is reversed on Surplus of share capital.

Other capital of the owner

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Treasury stocks

When repurchasing of stocks by the Company that issued them, the payments including transaction costs are recorded as treasury stocks and reflected as a deduction from owners' equity. When reissuing, differences between the reissue price and the book value of treasury stocks will be recorded into "Surplus of share capital".

11. Profit distribution

Profit after corporate income tax is distributed to shareholders after appropriating for funds in accordance with the Charter of Parent company and subsidiaries as well as regulations and being approved by General Meeting of Shareholders.

Distribution of profits to shareholders is considered non-monetary items in undistributed earnings after tax which can affect the cash flows and ability to pay dividends such as profit from revaluation of the contributed assets, revaluation of monetary items, financial instruments and other non-monetary items.

Dividends are recorded as liabilities when being approved by General Meeting of Shareholders.

12. Recognition of revenues and income

Revenues are recognized when the Company may get economic benefits that can be determined reliably. Revenues are measured at the fair value of received or receivable accounts after deducting trade discounts, sales discounts and sales returns.

Revenues from sale of merchandises (functional foods, cosmetics, ...) and sales of finished pharmaceutical products of all kinds

- Revenues from sale of merchandise, finished goods are recognized when satisfying the following conditions at the same time:
- Most of risk and benefits associated with the goods ownership are transferred to customers;
- There are no rights to manage or to control the goods;
- Revenues can be determined reliably;
- Getting or will get reliable economic benefits from providing service;
- Expenses related to providing and completing service can be determined.

Interest

Interest is recognized on an accrual basis, and determined on balance of savings accounts and the actual interest rates for each period

13. Revenue deductions

Revenue deductions are adjusted reductions of total revenue in year which include sales discounts and sales returns.

14. Cost of goods sold

Cost of goods sold is total cost of goods, production costs of finished goods sold, other expenses are included or recorded reducing in the cost of goods.

15. Expenses from financial activities

Expenses from financial activities are the costs related to financial activities include loss on foreign exchange.

16. Selling expenses and General & administration expenses

Selling expenses and General & administration expenses are all costs related to the process of selling products, goods, rendering of services and general administration expenses of the Company.

17. Transactions in foreign currencies

The transactions in foreign currencies are converted at the actual exchange rates ruling as of the transaction dates. The balances of monetary items in foreign currencies as at 31st December 2025 are converted at the actual exchange rates ruling on this date.

Foreign exchange differences arising during year from transactions in foreign currencies are recognized in income from financial activities or expenses from financial activities. Exchange rate differences due to the revaluation of monetary items in foreign currencies as at 31st December 2025 after offsetting differences of increasing and decreasing are recognized in income from financial activities or expenses from financial activities.

18. Corporate income tax

Corporate income tax expenses include current corporate income tax and deferred corporate income tax.

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

▪ Current Corporate income tax

Current corporate income tax expense is recognized based on taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between tax and accounting figures as well as those of non-taxable or non-deductible income and expenses.

▪ Deferred Corporate income tax

Deferred income tax is the amount of corporate income tax payable or refundable due to temporary differences between book values of assets and liabilities serving the preparation of the financial statements and the values for tax purposes. Deferred income tax liabilities are recognized for all the temporary taxable differences. Deferred income tax assets are recorded only when there is an assurance on the availability of taxable income in the future against which the temporarily deductible differences can be used.

Book values of deferred corporate income tax assets are considered at the balance sheet dates and will be reduced to the rates that ensure enough taxable income against which the benefits from a part of or all of the deferred income tax can be used. Deferred corporate income tax assets are not yet recorded in before that will be reconsidered as at the accounting period ended and recorded when being reliably taxable profit to be able to use deferred income tax assets.

Deferred income tax assets and deferred income tax liabilities are determined at the estimated rates to be applied in the year when the assets are recovered or the liabilities are settled based on the effective tax rates as of the balance sheet date. Deferred income tax is recognized in the income statement. In the case that deferred income tax is related to the items of the owner's equity, corporate income tax will be included in the owner's equity of the company.

Deferred income tax assets and deferred income tax liabilities should be offset when:

- The Company has a legal right to implement the offset of current income tax assets and current income tax payable; and
- Those deferred income tax assets and deferred income tax payable related to corporate income tax is administered by the same tax au
- For the same taxable entity; or
- The Company intends to pay current income tax payable and current income tax assets on the basis of net or recover assets at the same time with the payment of liabilities in each future period when the significant deferred income tax payable or deferred income tax assets to be paid or recovered.

19. Related parties

A party is considered as a related party of the company in case that party is able to control the company or to cause material effects on the financial decisions as well as the operations of the company. A party is also considered a related party of the company in case that party is under common control or significant influence.

In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form

20. Segment Reporting

A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of an enterprise that is engaged in providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

V. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE FINANCIAL STATEMENT**1. Cash and cash equivalents**

	Ending balance of period		Beginning balance	
	Foreign currencies	VND	Foreign currencies	VND
Cash on hand		601.703.815		562.362.624
Cash in banks		11.962.024.730		40.001.742.240
In which : USD deposits	1.541,98	40.678.259	1.548,58	40.846.895
EURO deposits				

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Cash equivalents	20.000.000.000	-
(Term deposits of 3 months or less)	20.000.000.000	-
Total	32.563.728.545	40.564.104.864

2. Held-to-maturity investments

	Ending balance of period	Beginning balance
(6-month term deposits)	500.000.000	500.000.000
Total	500.000.000	500.000.000

3. Trade receivables

	Ending balance of period	Beginning balance
Sales of products	51.823.851.593	34.720.871.572
Transferring raw material	-	-
Total	51.823.851.593	34.720.871.572

4. Advance payments to suppliers

	Ending balance of period	Beginning balance
Purchase of materials for production	2.661.104.135	3.527.687.775
Purchase of machinery and equipment for production	19.348.464.279	15.509.085.402
Other activities	7.576.410.983	12.738.385.354
Total	29.585.979.397	31.775.158.531

5. Other short-term receivables

	Ending balance of period	Beginning balance
Uncollected personal income tax	-	-
Other receivables	2.193.881.604	779.613.182
Estimated interest on term deposits from the deposit date to 31st December	1.684.932	1.684.932
Total	2.195.566.536	781.298.114

6. Inventories

	Ending balance of period	Beginning balance
Materials and supplies	75.232.539.450	44.716.722.244
Tools	687.319.418	687.319.418
Work-in-process	4.966.279.392	-
Finished goods	66.081.057.582	57.463.146.581
Merchandises	589.994	1.062.920.469
Total	146.967.785.836	103.930.108.712

7. Increase / Decrease tangible fixed assets

	Buildings and structures	Machineries and equipments	Vehicles	Tools management and other fixed assets	Total
Historical cost					
Beginning balance	33.321.724.375	221.326.508.533	21.312.809.053	13.219.657.137	289.180.699.098
Increase during period	-	18.755.016.966	-	45.000.000	18.800.016.966
New procurement	-	18.755.016.966	-	45.000.000	18.800.016.966

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Completed construction	-	-	-	-	-
Decrease during period	-	-	-	-	-
Disposal, liquidation					-
Ending balance of period	33.321.724.375	240.081.525.499	21.312.809.053	13.264.657.137	307.980.716.064
Depreciation					
Beginning balance	29.962.748.343	144.964.471.352	18.222.972.704	4.813.396.392	197.963.588.791
Increase during period	315.973.697	7.769.794.815	522.114.988	755.351.671	9.363.235.171
Depreciation during year	315.973.697	7.769.794.815	522.114.988	755.351.671	9.363.235.171
Decrease during period	-	-	-	-	-
Disposal, liquidation		-	-	-	-
Others					
Ending balance of period	30.278.722.040	152.734.266.167	18.745.087.692	5.568.748.063	207.326.823.962
Net book value					
Beginning balance	3.358.976.032	76.362.037.181	3.089.836.349	8.406.260.745	91.217.110.307
Ending balance of period	3.043.002.335	87.347.259.332	2.567.721.361	7.695.909.074	100.653.892.102
In which,					-

Historical cost of fully-depreciated tangible fixed assets is still in use 149.898.429.204 đồng

8. Increase / Decrease intangible fixed assets

	Land-use right	Computer software	Other intangible fixed assets	Total
Historical cost				
Beginning balance	2.916.105.767	3.849.899.609	1.291.759.533	8.057.764.909
Increase during period	-	13.530.000.000	-	13.530.000.000
Procurement during period	-	13.530.000.000	-	13.530.000.000
Decrease during period	-	-	-	-
Ending balance of period	2.916.105.767	17.379.899.609	1.291.759.533	21.587.764.909
Amortization				
Beginning balance	933.153.840	3.837.899.609	1.288.981.756	6.060.035.205
Increase during period	29.161.058	376.270.833	2.777.777	408.209.668
Amortization during period	29.161.058	376.270.833	2.777.777	408.209.668
Decrease during period	-	-	-	-
Ending balance of period	962.314.898	4.214.170.442	1.291.759.533	6.468.244.873
Net book value				
Beginning balance	1.982.951.927	12.000.000	2.777.777	1.997.729.704
Ending balance of period	1.953.790.869	13.165.729.167	-	15.119.520.036

In which,

Historical cost of fully-amortized intangible fixed assets is still in use 5.141.659.142 đồng

9. Short-term deferred costs

	Current year	Previous year
Insurance of all kinds	201.178.794	-
Tools and others	6.947.424.865	3.563.540.430
Total	7.148.603.659	3.563.540.430

10. Long-term deferred costs

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

		Current year	Previous year	
Repair of fixed assets and tools		24.642.209.303	30.215.513.211	
Other long-term prepaid expenses		-	-	
Total		24.642.209.303	30.215.513.211	
11. Short-term finance lease loans and liabilities		-	-	
	Beginning balance	Loan amount arising	Loan amount already paid	Ending balance
Short-term loans from banks	181.005.840	86.866.706.751	(181.005.840)	86.866.706.751
Total	181.005.840	86.866.706.751	(181.005.840)	86.866.706.751
12. Trade payables		Current year	Previous year	
Purchase of raw materials for production		25.715.352.421	24.779.214.999	
Purchase of machinery and equipment for production		1.819.097.042	2.450.000.521	
Purchase of other supplies for production		40.413.077	1.305.709.049	
Total		27.574.862.540	28.534.924.569	
13. Advance payments from customers		-	-	
		Current year	Previous year	
Purchase of products		1.681.830.588	1.940.919.537	
Others		-	-	
Total		1.681.830.588	1.940.919.537	
14. Dividends and profits must be paid.		-	-	
		Current year	Previous year	
		13.642.951.454	15.240.981.474	
15. Taxes and Statutory obligations				
	Beginning balance	Payable during period	Already paid during period	Ending balance of period
Output Value added tax (VAT)	-	-	-	-
Value added tax (VAT) on imports	-	2.265.464.789	2.265.464.789	-
Corporate income tax (CIT)	7.559.671.718	9.151.029.503	12.559.671.718	4.151.029.503
Personal income tax (PIT)	505.670.070	2.229.966.692	2.267.061.241	468.575.521
Resource tax	322.560	1.612.080	1.664.640	270.000
License tax	-			-
Real estate tax, land rent	-	4.173.312.803	2.096.935.175	2.076.377.628
Charges, duties and others	-	70.000.000	70.000.000	-
Total	8.065.664.348	17.891.385.867	19.260.797.563	6.696.252.652
16. Other short-term payables	-			-
		Current year	Previous year	
Social insurance, health insurance, unemployment insurance		380.893.805	-	
Short-term deposits and mortgages		881.000.000	351.000.000	
Dividends payable		13.642.951.454	15.240.981.474	
Selling expenses		182.737.567	198.864.502	
Others		8.980.000	11.576.943	
Total		15.096.562.826	15.802.422.919	
17. Bonus and welfare funds and Bonus fund for the Executive Management Board		-	-	

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

	Beginning balance	Increase from appropriation of profit	Decrease during period	Ending balance of period
Bonus fund	6.972.362.656	6.408.511.884	-6.523.084.900	6.857.789.640
Welfare fund	(547.627.486)	2.863.845.279	-4.556.087.000	(2.239.869.207)
Bonus fund for the Executive Management Board (Remuneration fund of the Board of Management)	957.693.611	2.048.494.128	-2.613.702.500	392.485.239
Total	7.382.428.781	11.320.851.291	(13.692.874.400)	5.010.405.672

18. Owners' equity
Bảng đối chiếu biến động của Vốn chủ sở hữu

Thông tin về biến động của vốn chủ sở hữu được trình bày trên Phụ lục đính kèm

Cổ phiếu

	Ending balance of period	Beginning balance
Number of stocks being registered to issue	9.332.573	9.332.573
Number of stocks already issued / public offering	9.332.573	9.332.573
- Common stocks	9.332.573	9.332.573
- Preferred stocks	-	-
Number of buy-back stocks	-	-
- Common stocks	-	-
- Preferred stocks	-	-
Number of outstanding stocks	9.332.573	9.332.573
- Common stocks	-	9.332.573
- Preferred stocks	-	-
Nominal value of outstanding stocks (VND/stock)	10.000	10.000
(**) Details of profit distribution are as follows:		
Beginning balance		53.306.348.102
Increase from business results during period		36.348.818.015
Reconcile the development investment fund with undistributed profits		93.250.277.906
Decrease during period, including:		24.713.882.630
- Make appropriation of Bonus and welfare funds and remuneration of the Board of Management and Supervisory Board from profit	11.648.280.430	
- From profit 2025	2.815.280.430	
- From profit 2026	8.833.000.000	
- Dividend payment (2nd tranche) for 2025	13.065.602.200	
Ending balance of period as at 30th June /2026	-	158.191.561.393

VI ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE INCOME STATEMENTS
1. Revenues from sale of goods and rendering of services

	Accumulated from the beginning of year to the end of this quarter	
	Current year	Previous year
Total revenues		
- Sale of goods	722.796.480	4.078.035.157
- Sale of finished goods	277.389.325.960	253.877.474.060
In which: Export	-	-
Total	278.112.122.440	257.955.509.217

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

2. Revenue deductions	16.182.253.004	-
	Current year	Previous year
- Returned goods	9.235.080	-
- Returned finished products, trade discounts	4.249.712.873	32.351.722
Total	4.258.947.953	32.351.722
3. Net revenues	-	-
- Sale of goods	672.231.721	4.078.035.157
- Finished goods	256.998.689.762	253.845.122.338
<i>In which: Export</i>	-	-
Total	257.670.921.483	257.923.157.495
4. Cost of goods sold	-	-
	Current year	Previous year
Goods sold	464.875.675	2.766.434.896
Finished goods sold	146.229.698.282	143.891.760.557
Total	146.694.573.957	146.658.195.453
5. Income from financial activities	-	-
	Current year	Previous year
Interest on term deposits	169.178.083	2.884.064.689
Interest on call deposits	23.143.451	18.977.240
Interest on realized exchange rate differences	3.317	-
Interest on unrealized exchange rate differences	-	-
Total	192.324.851	2.903.041.929
6. Expenses from financial activities	-	-
	Current year	Previous year
Interest expense	1.974.197.460	42.739.726
Total	1.974.197.460	42.739.726
7. Selling expenses	-	-
	Current year	Previous year
Employee costs	14.924.847.305	19.056.687.698
<i>Wages and salary</i>	12.684.445.470	16.774.000.993
<i>Trade union's fees, Social insurance, health insurance, unemployment insurance</i>	1.543.835.835	1.788.161.205
<i>Mid-shift meal costs</i>	696.566.000	494.525.500
Raw materials, tools	1.391.558.603	584.886.071
Depreciation / Amortization of fixed assets	99.364.101	521.120.818
Outsourcing expenses	880.194.822	1.140.463.240
Others	16.545.368.128	8.174.097.365
Total	33.841.332.959	29.477.255.192
8. General & administration expenses	-	-
	Current year	Previous year
Employee costs	15.177.504.058	19.752.987.297
<i>Wages and salary</i>	13.741.482.600	18.171.834.410
<i>Trade union's fees, Social insurance, health insurance, unemployment insurance</i>	1.091.396.458	1.292.649.887
<i>Mid-shift meal costs</i>	344.625.000	288.503.000

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Raw materials, management tools	3.092.484.348	354.820.394
Depreciation / Amortization of fixed assets	924.965.764	143.703.189
Taxes and duties	1.058.746.361	1.065.246.361
Outsourcing expenses	4.164.675.430	2.939.481.650
Others	5.432.750.030	4.624.239.163
Total	29.851.125.991	28.880.478.054
9. Other income		
	Current year	Previous year
Sale of liquidated fixed assets		664.545.455
Sale of raw materials	4.500.800	23.662.514
Overpayment from customers		
Scrap sales and internship guiding practice for students	69.766.307	21.339.344
Total	74.267.107	709.547.313
10. Other expenses		
	Current year	Previous year
Sale of raw materials	3.920.868	22.820.802
Penalties for administrative violations and others	72.514.688	70.000.000
Total	76.435.556	92.820.802
11. Current Corporate income tax (CIT) expenses		
	Current year	Previous year
Total pre-tax accounting profit	45.499.847.518	56.384.257.510
- - Increase adjustments	255.300.000	225.900.000
Taxable income	45.755.147.518	56.610.157.510
Corporate income tax (CIT) rate	20%	20%
Current Corporate income tax (CIT) expenses payable	9.151.029.503	11.322.031.502
12. Gains on stock		
	Current year	Previous year
Accounting profit after corporate income tax	36.348.818.015	45.062.226.008
Profit or loss is allocated for shareholders holding common stock	36.348.818.015	45.062.226.008
Average outstanding common stock during year	9.332.573	9.332.573
Gains on stock (VND/stock)	2.948	3.655
13. Expenses from operating activities by nature		
	Current year	Previous year
Raw materials	102.344.286.206	113.060.798.744
Employee costs	69.909.372.738	77.518.026.018
<i>Wages and salary</i>	60.228.919.427	67.336.473.013
<i>Trade union's fees, Social insurance, health insurance, unemployment insurance</i>	6.143.621.311	7.980.135.505
<i>Mid-shift meal costs</i>	3.536.832.000	2.201.417.500
Tools	9.731.038.000	1.257.929.332
Depreciation / Amortization of fixed assets	9.771.444.839	5.428.495.088
Outsourcing expenses	12.357.172.625	11.148.945.792
Others	24.681.717.467	15.230.713.103
Total	228.795.031.875	223.644.908.077

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

VII. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE AGGREGATED STATEMENT OF CASH FLOW (Currency: VND)**Loans to other entities and payments for purchase of debt instruments of other entities**

	Current year	Previous year
Term deposits at banks	(25.000.000.000)	111.500.000.000
Cộng	(25.000.000.000)	111.500.000.000

/III. OTHER INFORMATION**1 Relationship with related parties**

Related parties	Relationship	Contributed capital ratio
Saigon Pharmaceutical Company Limited (SAPHARCO)	Affiliate company	43,44%
PVI Infrastructure Investment Fund	Major shareholder	21,64%
Tasco Biologicals and Pharmaceuticals Co., Ltd.	Major shareholder	15,89%

2 Transactions during period with related parties

(*) Members of key management are members of the Board of Management, the Board of Directors and Chief Accountant

Transactions with related parties

	Accumulated from the beginning of year to the end of this quarter	
	Current year	Previous year
Saigon Pharmaceutical Company Limited (SAPHARCO)		
Beginning balance	9.451.611.493	15.034.969.582
Sales of finished products	25.236.181.872	20.423.870.566
Proceeds from sale of finished products	21.464.683.531	32.012.273.012
Ending balance of period	13.223.109.834	3.446.567.136
HA NOI BRANCH		
Beginning balance	1.591.544.539	2.366.944.147
Sales of finished products	2.216.013.219	2.209.219.045
Proceeds from sale of finished products	2.806.738.487	4.254.583.378
Ending balance of period	1.000.819.271	321.579.814
DA NANG BRANCH		
Beginning balance		1.356.781.913
Sales of finished products	2.726.336.386	3.275.264.249
Proceeds from sale of finished products	2.251.892.227	4.468.882.404
Ending balance of period	474.444.159	163.163.758
NHA TRANG BRANCH		
Beginning balance	52.944.346	1.117.719.605
Sales of finished products	734.776.329	269.236.224
Proceeds from sale of finished products	760.272.847	1.321.650.020
Ending balance of period	27.447.828	65.305.809
CAN THO BRANCH		
Beginning balance	-	-
Sales of finished products	2.883.339.670	-
Proceeds from sale of finished products	2.373.550.198	-
Ending balance of period	509.789.472	-
Tasco Biologicals and Pharmaceuticals Co., Ltd.		
Beginning balance	-	-
Sales of finished products	4.369.332.932	-

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the three-month period ended 30th June 2026

Proceeds from sale of finished products		-
Ending balance of period	4.369.332.932	-
Pharmedic Pharmaceutical Medicinal JSC - PHARMEDIC		
Beginning balance	-	-
Purchase of raw materials and goods		20.000.000.000
Payment to SAPHARCO for purchase of raw materials and goods		
Ending balance of period	-	20.000.000.000

All transactions with affiliated company as related parties are performed through economic contracts.

The selling price of products provided to related parties as well as the purchase price of raw materials from related parties are all made at market prices.

Accounts receivable are unsecured and will be paid in cash. Accounts receivable from related parties for which no provision has been made for doubtful debts.

Approve, 14th July 2026

Prepared by


 Trần Mạnh Hùng

Chief Accountant


 NGUYỄN DIỆU LÊ

General Director

